130 related articles for article (PubMed ID: 38281454)
21. Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma.
Yanagi M; Hamasaki T; Akatsuka J; Endo Y; Takeda H; Kondo Y
BMC Urol; 2021 Dec; 21(1):167. PubMed ID: 34856960
[TBL] [Abstract][Full Text] [Related]
22. Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study.
Hung YP; Liu CJ; Hu YW; Chen MH; Li CP; Yeh CM; Chiou TJ; Chen TJ; Yang MH; Chao Y
Medicine (Baltimore); 2015 Sep; 94(38):e1626. PubMed ID: 26402833
[TBL] [Abstract][Full Text] [Related]
23. Clinical and demographic characteristics among patients with urothelial carcinomas of the upper urinary tract and bladder in Taiwan.
Shen CH; Chiou HY; Tung MC; Wu CC; Kao WT; Wang YH; Juang GD
J Chin Med Assoc; 2017 Sep; 80(9):563-568. PubMed ID: 28751166
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours.
Yates DR; Rouprêt M; Drouin SJ; Audouin M; Cancel-Tassin G; Comperat E; Bitker MO; Cussenot O
World J Urol; 2013 Feb; 31(1):53-9. PubMed ID: 23053209
[TBL] [Abstract][Full Text] [Related]
25. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
Yates DR; Catto JW
World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
[TBL] [Abstract][Full Text] [Related]
26. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy.
Ishioka J; Saito K; Kijima T; Nakanishi Y; Yoshida S; Yokoyama M; Matsuoka Y; Numao N; Koga F; Masuda H; Fujii Y; Sakai Y; Arisawa C; Okuno T; Nagahama K; Kamata S; Sakura M; Yonese J; Morimoto S; Noro A; Tsujii T; Kitahara S; Gotoh S; Higashi Y; Kihara K
BJU Int; 2015 May; 115(5):705-12. PubMed ID: 24612074
[TBL] [Abstract][Full Text] [Related]
27. Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national population-based cohort study.
Liao CI; Fang HC; Lee PT; Hsu CY; Chen CL; Huang CW; Chen XY; Ou SH; Tsai CT; Chou KJ
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8201-8211. PubMed ID: 37061628
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan.
Lee YT; Liu CJ; Hu YW; Teng CJ; Tzeng CH; Yeh CM; Chen TJ; Lin JK; Lin CC; Lan YT; Wang HS; Yang SH; Jiang JK; Chen WS; Lin TC; Chang SC; Chen MH; Teng HW; Liu JH; Yen CC
Medicine (Baltimore); 2015 Jul; 94(26):e1079. PubMed ID: 26131831
[TBL] [Abstract][Full Text] [Related]
29. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma.
Chung SD; Huang KH; Lai MK; Huang CY; Chen CH; Pu YS; Yu HJ; Chueh SC
Am J Kidney Dis; 2007 Nov; 50(5):743-53. PubMed ID: 17954287
[TBL] [Abstract][Full Text] [Related]
30. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
[TBL] [Abstract][Full Text] [Related]
31. Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017.
van Doeveren T; van der Mark M; van Leeuwen PJ; Boormans JL; Aben KKH
BJU Int; 2021 Sep; 128(3):343-351. PubMed ID: 33690922
[TBL] [Abstract][Full Text] [Related]
32. High incidence of and risk factors for metachronous bilateral upper tract urothelial carcinoma in Taiwan.
Huang PC; Huang CY; Huang SW; Lai MK; Yu HJ; Chen J; Pu YS
Int J Urol; 2006 Jul; 13(7):864-9. PubMed ID: 16882044
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a prognostic nomogram for patients with intravesical recurrence after radical nephroureterectomy for non-metastatic upper tract urothelial carcinoma.
Hou G; Zheng Y; Zhang L; Lai D; Wang F; Li X; Yan F; Tian J; Zhang G; Meng P; Wei D; Zhu Z; Yuan J; Hui Q; Yuan J
World J Urol; 2020 Aug; 38(8):1969-1975. PubMed ID: 31654221
[TBL] [Abstract][Full Text] [Related]
34. Preoperative Pyuria Predicts for Intravesical Recurrence in Patients With Urothelial Carcinoma of the Upper Urinary Tract After Radical Nephroureterectomy Without a History of Bladder Cancer.
Sato G; Yoshida T; Yanishi M; Saito R; Murota T; Kawa G; Kinoshita H; Matsuda T
Clin Genitourin Cancer; 2020 Apr; 18(2):e167-e173. PubMed ID: 31635939
[TBL] [Abstract][Full Text] [Related]
35. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
Dickman KG; Chen CH; Grollman AP; Pu YS
World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
[TBL] [Abstract][Full Text] [Related]
36. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration).
Katims AB; Say R; Derweesh I; Uzzo R; Minervini A; Wu Z; Abdollah F; Sundaram C; Ferro M; Rha K; Mottrie A; Rosiello G; Simone G; Eun DD; Reese A; Kidd LC; Porter J; Bhattu AS; Gonzalgo ML; Margulis V; Marcus J; Danno A; Meagher M; Tellini R; Mari A; Veccia A; Ghoreifi A; Autorino R; Djaladat H; Mehrazin R
J Urol; 2021 Sep; 206(3):568-576. PubMed ID: 33881931
[TBL] [Abstract][Full Text] [Related]
38. Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan-Japan UTUC Collaboration Cohort.
Luo HL; Ohyama C; Hatakeyama S; Wang HJ; Yoneyama T; Yang WC; Chuang YC; Chen YT; Lee WC; Cheng YT; Kang CH; Chiang PH
Int J Urol; 2020 Apr; 27(4):327-332. PubMed ID: 32100370
[TBL] [Abstract][Full Text] [Related]
39. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
[TBL] [Abstract][Full Text] [Related]
40. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N; Kita Y; Ito K; Kato M; Hatakeyama S; Matsushita Y; Naito S; Miyake M; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Nishiyama H; Kobayashi T; Kitamura H;
Anticancer Res; 2023 Nov; 43(11):5041-5050. PubMed ID: 37909969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
